ABBV vs BNR

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

The company exhibits a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe fundamental deterioration. Despite a strong gross margin of 73.02% and a healthy current ratio of 3.15, persistent unprofitability (negative ROE, ROA, and profit margin) and deeply negative earnings surprises over the past 12 quarters undermine any value proposition. The stock's recent 1Y price surge of +414.2% appears disconnected from fundamentals, especially given the lack of analyst coverage, no meaningful dividend, and deteriorating earnings trajectory. While the low debt/equity ratio is favorable, the absence of an Altman Z-Score and deeply negative Forward P/E (-60.47) signal high distress risk and speculative valuation.